07:00 Wed 25 Aug 2021
EKF Diagnostics Hldg - Notice of Results
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Notice of Results
Investor briefing
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, will announce its interim results for the six months ended
Investor briefing
EKF Diagnostics will be hosting a live online presentation open to all investors on Wednesday
EKF Diagnostics Holdings plc |
||
|
Tel: +44 (0) 29 2071 0570 |
|
|
|
|
|
|
|
|
|
|
Singer Capital Markets |
Tel: 020 7496 3000 |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: +44 (0) 20 7933 8780 or ekf@walbrookpr.com |
|
|
Mob: +44 (0) 7980 541 893 / +44 (0) 7584 391 303 |
|
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE